Hologic Inc. (HOLX) shares plummeted by 5.49% in pre-market trading on Thursday, following a series of analyst downgrades after the company reported its fiscal first-quarter results.
Leerink downgraded HOLX to Market Perform from Outperform with a lower price target of $75, down from $80, citing the mixed Q1 report. Jefferies also cut its price target on the stock to $78 from $85, while JP Morgan lowered its target to $85 from $94.
The downgrades came as analysts expressed concerns over the company's outlook and financial performance. Hologic's Q1 results fell short of market expectations, leading analysts to revise their ratings and price targets accordingly.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。